Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Total Liabilities (2016 - 2025)

INVO Fertility (IVF) has disclosed Total Liabilities for 15 consecutive years, with $13.0 million as the latest value for Q3 2025.

  • Quarterly Total Liabilities fell 23.82% to $13.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Sep 2025, down 23.82% year-over-year, with the annual reading at $26.2 million for FY2024, 49.01% up from the prior year.
  • Total Liabilities for Q3 2025 was $13.0 million at INVO Fertility, down from $16.7 million in the prior quarter.
  • The five-year high for Total Liabilities was $26.2 million in Q4 2024, with the low at $2.5 million in Q1 2022.
  • Average Total Liabilities over 5 years is $11.0 million, with a median of $6.6 million recorded in 2023.
  • The sharpest move saw Total Liabilities crashed 49.13% in 2022, then soared 459.65% in 2023.
  • Over 5 years, Total Liabilities stood at $2.7 million in 2021, then soared by 74.69% to $4.7 million in 2022, then skyrocketed by 275.75% to $17.6 million in 2023, then soared by 49.01% to $26.2 million in 2024, then crashed by 50.53% to $13.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $13.0 million, $16.7 million, and $24.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.